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ABSTRACT
Background
Patients infected with HIV-1 initiating antiretroviral therapy (ART) containing a non-
nucleoside reverse transcriptase inhibitor (NNRTI) show presumably fewer atherogenic lipid
changes than those initiating most ARTs containing a protease inhibitor. We analysed whether
lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and
efavirenz (EFV).
Methods and Findings
Prospective analysis of lipids and lipoproteins was performed in patients enrolled in the NVP
and EFV treatment groups of the 2NN study who remained on allocated treatment during 48
wk of follow-up. Patients were allocated to NVP (n=417), or EFV (n=289) in combination with
stavudine and lamivudine. The primary endpoint was percentage change over 48 wk in high-
density lipoprotein cholesterol (HDL-c), total cholesterol (TC), TC:HDL-c ratio, non-HDL-c, low-
density lipoprotein cholesterol, and triglycerides. The increase of HDL-c was significantly larger
for patients receiving NVP (42.5%) than for patients receiving EFV (33.7%; p=0.036), while the
increase in TC was lower (26.9% and 31.1%, respectively; p=0.073), resulting in a decrease of
the TC:HDL-c ratio for patients receiving NVP ( 4.1%) and an increase for patients receiving EFV
(þ5.9%; p , 0.001). The increase of non-HDL-c was smaller for patients receiving NVP (24.7%)
than for patients receiving EFV (33.6%; p=0.007), as were the increases of triglycerides (20.1%
and 49.0%, respectively; p , 0.001) and low-density lipoprotein cholesterol (35.0% and 40.0%,
respectively; p=0.378). These differences remained, or even increased, after adjusting for
changes in HIV-1 RNA and CD4þcell levels, indicating an effect of the drugs on lipids over and
above that which may be explained by suppression of HIV-1 infection. The increases in HDL-c
were of the same order of magnitude as those seen with the use of the investigational HDL-c-
increasing drugs.
Conclusion
NVP-containing ART shows larger increases in HDL-c and decreases in TC:HDL-c ratio than an
EFV-containing regimen. Based on these findings, protease-inhibitor-sparing regimens based
on non-nucleoside reverse transcriptase inhibitor, particularly those containing NVP, may be
expected to result in a reduced risk of coronary heart disease.
Introduction
Numerous large epidemiological studies have unambiguously demonstrated a strong inverse
relationship between the plasma concentration of high-density lipoprotein cholesterol (HDL-c)
and the incidence of coronary heart disease (CHD) [1,2]. Recent attempts to develop therapies
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e19 064
Open access, freely available online PLoS MEDICINEaimed at increasing HDL-c as innovative CHD-risk-reducing
strategies illustrate the potential of HDL-c as a potent anti-
atherogenic mediator [3,4,5,6].
Combination antiretroviral therapy (ART) for the treat-
ment of HIV-1 infection has been associated with fat
redistribution, insulin resistance, and changes in plasma
concentrations of lipids and lipoproteins [7,8,9]. Each of these
phenomena is associated with increased CHD risk in the
general population. It is not surprising, therefore, that in the
setting of HIV-1 infection, increasing exposure to potent
combination ART has been demonstrated to be associated
with an incremental risk of CHD in a recent prospective
study [10]. Interestingly, however, the changes in lipids and
lipoproteins differ between patients using an ART regimen
containing either a protease inhibitor (PI) or a non-nucleo-
side reverse transcriptase inhibitor (NNRTI). Whereas many
of the PI-based regimens are often associated with increased
levels of triglycerides (TGs), total cholesterol (TC), and low-
density lipoprotein cholesterol (LDL-c) [8,9,11], NNRTI-based
regimens importantly differ from PI-based regimens by being
associated with marked increases of HDL-c and lesser
increases of LDL-c and TGs [12,13]. Notably, the increases
in HDL-c demonstrated with NNRTI-containing ART mark-
edly exceed those that may be induced with any of the
currently licensed statins or ﬁbrates [14].
Although as yet no clinical data have been generated to
support this, these differences between ART regimens raise
the expectation that NNRTI-based regimens, particularly in
view of their effects on HDL-c, may favourably modify the
CHD risk compared with many of the PI-containing
regimens. With respect to the two currently commonly used
NNRTIs, nevirapine (NVP) and efavirenz (EFV), no detailed
comparative data have been reported concerning their effect
on plasma lipids and HDL-c in particular.
We prospectively analysed lipid and lipoprotein changes in
a preplanned substudy of the 2NN trial in which ART-naive
patients received stavudine (d4T) and lamivudine (3TC) with
the randomly assigned addition of NVP, EFV, or both drugs
combined.
Methods
Participants and Treatment Allocation
The 2NN trial was an open-label study, the main results of
which have been published elsewhere [15]. Patients enrolled
were 16 y of age or older, ART-naive, and had a plasma HIV-1
RNA concentration (pVL) of at least 5,000 copies/ml. Main
exclusion criteria were pregnancy or breastfeeding, abnormal
laboratory results at screening, the use of immuno-modulat-
ing therapy, or anticipated nonadherence. All patients used
d4T (40 mg twice daily [bd] or 30 mg bd when less than 60 kg)
and 3TC (150 mg bd). In addition, patients were randomly
allocated to NVP at 400 mg once daily (od), NVP at 200 mg
bd, EFV at 600 mg od, or NVP and EFV at 400 mg od and 800
mg od, respectively. Patients were included from 65 different
study sites in 17 countries in Asia, Australia, North America,
South America, South Africa, and Europe. The 2NN study
had been approved by the ethics committees of all partic-
ipating institutions, and all patients had given written
informed consent.
The current analyses were preplanned. Only those patients
were included who used all components of their allocated
treatment for at least 95% of the time during the 48 wk of
follow-up (self-reported). Change of d4T and/or 3TC was
allowed for reasons of toxicity. Employing such ‘on treatment’
(OT) analysis, allows the best possible assessment of lipid
changes that actually result from differences in regimens.
Patients in the NVP-od and NVP-bd groups were combined,
given that the virologic efﬁcacy of these treatments was
comparable and no differences in risk of virologic failure
were observed.
Follow-Up and Assessments
Plasma samples for prospective determination of lipids and
lipoproteins were collected at baseline (before start of
treatment) and at weeks 2, 4, 8, 12, 24, 36, and 48. Blood
was drawn after a mandatory fast of at least 3 h. The samples
were analysed in local laboratories according to predeﬁned
protocols. These laboratories were selected by the Virtual
Central Laboratory (Zeist, The Netherlands), which selected
the laboratories, assured the quality of the analyses and data,
and standardised all results. Plasma concentrations of HDL-c,
TC, and TGs were assessed by standard enzymatic assays. The
concentration of LDL-c was calculated using the Friedewald
equation, but only when the concentration of TGs was below
4.5 mmol/l [16]. Because the calculation of LDL-c depends on
the measured TG concentrations and these TG levels might
be biased because of the relatively short mandatory fasting
period, we also calculated the non-HDL-c levels. These are
considered to be much less inﬂuenced by TG levels. The pVL
was measured at a central laboratory (LabCorp, Research
Triangle Park, North Carolina, United States) using Ultra
Sensitive Roche Amplicor 1.5 (Roche Diagnostics, Basel,
Switzerland) with a lower limit of quantiﬁcation of 50
copies/ml.
Outcome Measurements
The primary study outcome was the mean percentage
change of HDL-c, TC, TC:HDL-c ratio, non-HDL-c, LDL-c,
and TGs between start of allocated treatment and week 48.
For each patient at each speciﬁc study week we calculated this
estimate as concentration at week X minus concentration at
baseline divided by concentration at baseline, times 100.
Study-week-speciﬁc estimates were used for the subsequent
analyses.
Factors assessed for a possible association with the primary
outcome were sex, study region (Asia/Australia, South Africa,
South America, Europe/North America), body mass index
(BMI) (continuous), increase between start of therapy and
week 48 in CD4þcells (,100, 100–250, or .250 cells/mm
3)o r
decrease in pVL (,2.5, 2.5–3.5, or .3.5 log10), and virologic
failure during follow-up. Virologic failure was deﬁned as (1)
never having obtained a pVL of less than 50 copies/ml or (2) a
rebound to two consecutive pVLs of  50 copies/ml. A single
pVL of  50 copies/ml at week 48 was also considered a
virologic failure.
Statistical Analyses
The analyses included the NVP and EFV treatment groups
only. This choice was made since the results of the main 2NN
study clearly showed that the simultaneous use of NVP and
EFV shouldn’t be recommended in clinical practice in view of
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increased virologic efﬁcacy.
The mean percentage changes in lipid concentrations were
modelled using a mixed model incorporating repeated
measurements. This model handles missing data adequately
by estimating the outcome of a speciﬁc variable based on the
available data given the speciﬁed covariate structure. The
variables (ﬁxed effects) in the model were tested for
signiﬁcance using the Type III F-statistic. The estimates of a
speciﬁc level of the ﬁxed effect were modelled using the ‘least
squared means’ approach. Differences in these estimates
between different levels of the variable were tested for
signiﬁcance using the t-statistic.
Since the analyses might be biased because of the OT
approach or the modelling of data, we performed two
sensitivity analyses. The ﬁrst was an analysis using the same
modelling strategy but for an intention-to-treat population
including all patients who started their randomised treat-
ment. The second was an analysis using only available data for
the OT population, without modelling of data points.
Independent risk factors were assessed by multivariable
regression analyses. The multivariable analysis included the
variable ‘treatment group’ and all predeﬁned variables.
Interaction between treatment group and a speciﬁc variable
was assumed at a p-value less than 0.15. A two-sided p-value
less than 0.05 was considered statistically signiﬁcant in the
ﬁnal analyses. The SAS statistical package was used for
analyses (version 8.02, SAS Institute, Cary, North Carolina,
United States).
Results
Disposition of Patients
Of the 1,216 patients included in the 2NN study, 607 were
allocated to the NVP treatment group and 400 to the EFV
treatment group. Of these, 42 (6.9%) patients in the NVP
group and 25 (6.3%) patients in the EFV group did not start
their treatment or were considered a ‘study entry violator’ by
a (blinded-to-treatment) independent endpoint committee.
These patients were excluded from the analyses. From the
remaining patients (565 using NVP and 375 using EFV), only
those who remained on their assigned treatment during the
follow-up were included in the analyses. This resulted in a
ﬁnal sample size of 417 (68.7%) patients in the NVP group
and 289 (72.3%) in the EFV group.
All of the included patients had at least one measurement
of each lipid parameter and could therefore be used in the
statistical models. The baseline characteristics of the subset of
patients included in the current analyses are summarised in
Table 1. These baseline characteristics were comparable with
those of all patients enrolled in the main 2NN study.
In the NVP group, 148 of the 565 eligible patients (26.2%)
were not included in the OT analyses. Of these 96 (65%) were
nonadherent (including patients lost to follow-up while on
randomised treatment), 30 (20%) changed their NNRTI to
EFV, and 22 (15%) changed their regimen by adding a PI. In
the EFV group, 76 of the 375 eligible patients (20.3%) were
not included in the OT analyses. Of these 54 (71%) were
nonadherent, 17 (22%) changed their NNRTI to NVP, 3 (4%)
added a PI, and 2 (3%) added a third nucleoside reverse
transcriptase inhibitor.
Changes in Lipids and Lipoproteins
All changes within the treatment groups in lipid and
lipoprotein concentration, as well as in TC:HDL-c ratio were
statistically signiﬁcant.
The increase of HDL-c was 8.9% (95% conﬁdence interval
[CI], 0.6–17.1) larger in the NVP treatment group (42.5%)
than in the EFV treatment group (33.7%). This was statisti-
cally signiﬁcant (p=0.036) (Table 2). In contrast, the increase
Table 1. Baseline Characteristics of Patients Included in the 2NN Lipid Substudy and the 2NN Main Study
Patients Taking NVP
(n = 417)
Patients Taking EFV
(n = 289)
Total Patients
(n = 706)
Patients in 2NN Main
(n = 1,216)
Male, n (%) 261 (63) 185 (64) 446 (63) 772 (63)
Age, median (IQR) 35 (29–42) 35 (30–40) 35 (30–40) 34 (29–40)
BMI, median (IQR) 20 (18–22) 19 (17–22) 20 (17–22) 19 (17–22)
Region, n (%)
Asia/Australia 74 (18) 62 (22) 136 (19) 223 (18)
South Africa 145 (35) 108 (37) 253 (36) 430 (35)
South America 87 (21) 61 (21) 148 (21) 249 (21)
Europe/North America 107 (26) 58 (20) 165 (23) 314 (26)
CD4þ cells, cells/mm
3 median (IQR) 180 (70–310) 190 (70–350) 180 (70–330) 190 (70–330)
HIV-1 RNA, log10 median (IQR) 4.6 (4.4–5.4) 4.7 (4.4–5.5) 4.7 (4.5–5.5) 4.7 (4.4–5.5)
CDC-class C, n (%) 89 (21) 58 (20) 147 (21) 253 (21)
Risk behaviour, n (%)
Heterosexual 244 (59) 161 (56) 405 (57) 695 (57)
Homosexual 115 (27) 93 (32) 208 (29) 350 (29)
Intravenous drugs 15 (4) 8 (3) 23 (3) 55 (5)
Other/unknown 43 (10) 27 (9) 70 (10) 116 (10)
IQR, interquartile range.
DOI: 10.1371/journal.pmed.0010019.t001
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group (31.1%), but this difference ( 4.2%; 95% CI,  8.7 to
0.4) was not statistically signiﬁcant (p=0.073). These changes
resulted in a decrease of the TC:HDL-c ratio in the NVP
group ( 4.1%) compared to an increase in the EFV group
(þ5.9%; p , 0.001), and a signiﬁcantly smaller increase of
non-HDL-c in the NVP group (difference,  8.9%; 95% CI,
 15.4 to  2.5; p=0.007).
The increase of TGs was 28.9% (95% CI,  42.3 to  5.0)
smaller in the NVP group (20.1%) than in the EFV group
(49.0%; p , 0.001). The difference in LDL-c increase was not
statistically signiﬁcant (35.4% for NVP group; 40.0% for EFV
group; p=0.378).
In the ﬁrst sensitivity analysis (intention-to-treat popula-
tion), the increases of HDL-c were slightly lower (41.2% for
NVP group; 32.4% for EFV group), just as for TC (26.1% for
NVP group, 30.4% for EFV group) and non-HDL-c (24.3%
for NVP group, 33.1% for EFV group). The TC:HDL-c ratio
showed a smaller decrease for patients taking NVP ( 2.6%)
but a larger increase for patients taking EFV (þ7.2%). The
increase in TGs was larger for both patients taking NVP
(24.3%) and patients taking EFV (49.3%). The LDL-c increase
was somewhat smaller for patients taking NVP (33.1%) but
larger for patients taking EFV (47.3%).
The difference between patients taking NVP and those
taking EFV for HDL-c (8.8%; 95% CI, 1.3 16.3) remained
statistically signiﬁcant, just as the difference in the TC:HDL-c
ratio ( 9.8%; 95% CI, 14.7 to 4.9), non-HDL-c ( 8.8%; 95%
CI,  14.6 to  3.0), and TGs ( 24.9%; 95% CI,  37.2 to –12.6).
Additionally, the difference between NVP and EFV treatment
groups became statistically signiﬁcant for TC ( 4.2%; 95% CI,
 8.5 to 0.0) and LDL-c ( 14.2%; 95% CI,  28.4 to 0.0)
compared to the original OT analysis. The second sensitivity
analysis (using only available data for the OT population) also
showed comparable estimates (data not shown).
The increase in HDL-c for patients who started their ART
when their HDL-c levels were, according to the National
Cholesterol Education Program (NCEP) guidelines, low
(,1.03 mmol/l), normal (1.03–1.55 mmol/l), or high (.1.55
mmol/l) is reported in Table 3. In both treatment groups, the
majority of patients had a low HDL-c at the start of therapy.
These patients showed the largest increase in HDL-c over 48
wk. Even patients with a normal baseline HDL-c level showed
statistically signiﬁcant, marked increases of HDL-c. The effect
of baseline HDL-c level on percentage increase was com-
parable in both treatment groups (interaction, p=0.409).
Multivariable Analysis
Factors independently associated with changes in the lipid
concentrations were analysed by a multivariable regression
analysis (Table 4).
Men had a signiﬁcantly smaller increase of HDL-c,
compared to women, but a larger increase of TC. This
resulted in an increased TC:HDL-c ratio for men and a
Table 2. Lipid Concentrations at Baseline and Week 48 and Mean Percentage Change
Lipid Patients Taking NVP (n = 417) Patients Taking EFV (n = 289) Difference
(NVP   EFV)
(95% CI)
p-Value
for Difference Week 0
a Week 48
a Percent
Increase
b
Week 0 Week 48 Percent
Increase
TC 3.9 (3.3–4.6) 4.9 (4.1–5.7) 26.9 (1.5) 3.9 (3.4–5.9) 5.0 (4.3–5.9) 31.1 (1.8)  4.2 ( 8.7 to 0.4) 0.073
HDL-c 1.0 (0.8–1.2) 1.3 (1.1–1.6) 42.5 (2.7) 1.0 (0.8–1.2) 1.2 (1.0–1.5) 33.7 (3.2) 8.9 (0.6 to 17.1) 0.036
Non-HDL-c 3.0 (2.3–3.6) 3.5 (2.7–4.3) 24.7 (2.1) 3.0 (2.4–3.5) 3.6 (3.0–4.7) 33.6 (2.5)  8.9 ( 15.4 to  2.5) 0.007
LDL-c 2.2 (1.7–2.9) 2.8 (2.2–3.5) 35.4 (3.4) 2.3 (1.9–2.9) 2.9 (2.4–3.8) 40.0 (4.0)  4.6 ( 14.9 to 5.7) 0.378
TGs 1.2 (0.8–1.8) 1.2 (0.8–2.2) 20.1 (4.4) 1.2 (0.8–1.7) 1.4 (0.9–2.3) 49.0 (5.3)  28.9 ( 42.3 to  15.5) ,0.001
TC:HDL-c ratio 4.2 (3.3–5.0) 3.7 (2.9–4.7)  4.1 (1.6) 4.2 (3.3–5.0) 4.2 (3.3–5.2) 5.9 (1.9)  10.0 ( 14.9 to  5.0) ,0.001
All percentage changes within a treatment group were statistically significant.
a Units: mmol/l, median (interquartile range).
b Mean percentage change (standard error), modeled by repeated measurements. Mean percentage change was calculated at each specific time point for each individual
patient as ((concentration[week X] – concentration[baseline]) / concentration[baseline]) 3 100.
DOI: 10.1371/journal.pmed.0010019.t002
Table 3. Increase in HDL-c Stratified by Baseline HDL-c (NCEP Categories)
NCEP Category Nevirapine (n = 417) EFV (n = 289) p-Value
n (%) Percent Increase
a n (%) Percent Increase
Low (,1.03 mmol/l) 251 (60.2) 53.7 (3.0) 173 (59.9) 51.1 (4.3) 0.698
Normal (1.03–1.55) 140 (33.6) 30.8 (4.0) 95 (32.9) 11.1 (5.7) ,0.001
High (.1.55 mmol/l) 26 (6.2)  0.9 (9.5) 21 (7.3)  5.7 (12.1) 0.614
a Mean percentage change (standard error), modeled by repeated measurements. Mean percentage change was calculated at each specific time point for each individual
patient as ((concentration[week X] – concentration[baseline]) / concentration[baseline]) 3 100.
DOI: 10.1371/journal.pmed.0010019.t003
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was signiﬁcantly larger in men.
The changes in lipid concentrations varied markedly by
region. Patients from Asia/Australia and South Africa had the
largest decrease in the TC:HDL-c ratio because of an increase
of HDL-c that outweighed the increase of TC. Patients from
South America, compared to those from other regions, had a
signiﬁcantly smaller HDL-c increase with a comparable TC
increase, resulting in an increased TC:HDL-c ratio. Although
patients from Europe showed the largest change in HDL-c,
the increases in TC and TC:HDL-c ratio were intermediate. A
striking ﬁnding is the much larger increase of TGs in patients
from South America compared to those in patients from
other regions, which to a lesser extent was also seen for non-
HDL-c.
For all lipid concentrations, except TGs, there was a clear
pattern of larger increases of lipid levels with larger decreases
of pVL over 48 wk. This was also seen when the pVL increase
over 48 wk was analysed as a continuous variable. For each
log10 larger decrease in pVL there was a 4.6% increase in TC
(p , 0.001), a 7.8% increase in HDL-c (p , 0.001), a 10.2%
increase in LDL-c (p , 0.001), and a 3.6% increase in non-
HDL-c (p=0.002), while the TC:HDL-c ratio declined with
1.6% (p=0.051). In this analysis, there was also a clear
association between pVL decline and change in TGs (6.3%
decline per log10; p=0.002).
In general, a smaller CD4þ-cell increase was associated with
a smaller increase in lipid concentration, while increases of
more than 250 cells/mm
3 did not show markedly different
effects compared to increases of 100–250 cells/mm
3. When
analysed as a continuous variable, there was no statistically
signiﬁcant association between CD4þ-cell increase and
change in any of the lipid parameters.
BMI was independently associated with increases in all lipid
parameters, except TC. Although the increases per unit
increase in BMI were statistically signiﬁcant, the magnitude of
increases was rather low.
All these factors exhibited a similar effect in both the NVP
and the EFV treatment group (no signiﬁcant interactions).
There were, however two exceptions. For changes in TGs, the
effect of sex and pVL decrease differed between the treat-
ment groups (interaction, p=0.005 and p=0.075,
Table 4. Factors Associated with Percentage Change in Lipid Parameters (Multivariable Analyses)
TC HDL-c TC:HDL-c Ratio Non-HDL-c LDL-c TGs
Base
a Percent
Increase
b
Base Percent
Increase
Base Percent
Increase
Base Percent
Increase
Base Percent
Increase
Base Percent
Increase
Sex
Male 3.9 24.4 (1.0) 0.9 29.4 (1.9) 4.3 1.4 (1.1) 2.9 24.5 (1.5) 2.2 34.1 (2.8) 1.3 27.6 (2.7)
Female 4.0 22.2 (1.3) 1.0 34.3 (2.3) 3.9  4.6 (1.4) 3.0 19.8 (1.9) 2.4 30.5 (3.5) 1.0 12.0 (3.4)
p-Value
c 0.103 0.045 ,0.001 0.021 0.326 ,0.001
Region
d
A 4.1 24.2 (1.6) 0.9 33.7 (3.0) 4.6  4.2 (1.8) 3.1 21.2 (2.5) 2.4 34.9 (4.5) 1.4 21.0 (4.3)
B 4.0 20.7 (1.2) 0.9 33.5 (2.2) 4.4  6.2 (1.3) 3.0 16.7 (1.8) 2.5 26.2 (3.2) 1.0 13.5 (3.2)
C 3.7 25.0 (1.5) 1.0 25.5 (2.7) 3.7 4.5 (1.6) 2.6 26.8 (2.2) 2.1 31.0 (4.1) 1.1 32.5 (4.0)
D 3.9 23.3 (1.6) 1.0 34.6 (2.9) 4.0  0.5 (1.7) 2.8 23.9 (2.4) 2.3 37.2 (4.3) 1.3 12.3 (4.2)
p-Value 0.052 0.029 ,0.001 ,0.001 0.092 ,0.001
BMI (per unit) 0.2 (0.2)  0.7 (0.3) 0.7 (0.2) 0.6 (0.3) 1.0 (0.5) 1.1 (0.5)
p-Value 0.179 0.028 ,0.001 0.023 0.037 0.022
pVL decrease (log10)
,2.5 4.1 18.6 (1.5) 1.0 23.5 (2.6) 3.9  0.4 (1.6) 3.1 18.3 (2.2) 2.5 22.5 (3.9) 1.0 23.4 (3.9)
2.5–3.5 4.0 22.5 (1.2) 1.0 31.4 (2.2) 4.1  0.9 (1.3) 3.0 21.9 (1.8) 2.3 29.7 (3.3) 1.1 26.9 (3.2)
.3.5 3.8 28.9 (1.4) 0.9 40.7 (2.6) 4.4  3.5 (1.6) 2.8 26.2 (2.1) 2.1 44.7 (3.9) 1.5 9.2 (3.8)
p-Value ,0.001 ,0.001 0.221 0.018 ,0.001 ,0.001
CD4þ increase (cells/mm
3)
,100 4.0 21.6 (1.4) 1.0 28.3 (2.5) 4.0  0.7 (1.5) 3.0 20.4 (2.0) 2.3 28.3 (3.7) 1.1 20.0 (3.6)
100–250 3.9 25.1 (1.2) 0.9 37.9 (2.2) 4.4  3.7 (1.3) 3.0 23.6 (1.8) 2.3 34.3 (3.2)) 1.2 18.3 (3.2)
.250 3.9 23.3 (1.4) 1.0 29.3 (2.6) 4.1  0.4 (1.6) 2.9 22.3 (2.1) 2.3 34.3 (3.9) 1.2 21.2 (3.8)
p-Value 0.066 ,0.001 0.073 0.378 0.312 0.755
Virologic failure
No 3.9 22.7 (0.8) 1.0 32.5 (1.5) 4.2  2.0 (0.9) 3.0 21.5 (1.2) 2.3 31.2 (2.2) 1.2 14.1 (2.2)
Yes 3.9 24.0 (1.7) 0.9 31.1 (3.0) 4.2  1.2 (1.8) 2.8 22.7 (2.5) 2.3 33.4 (4.5) 1.2 25.5 (4.4)
p-Value 0.471 0.663 0.657 0.650 0.642 0.017
a Units: mmol/l.
b Percentage increase (standard error) between baseline and week 48, modelled by repeated measurements. Mean percentage change was calculated at each specific time
point for each individual patient as ((concentration[week X] – concentration[baseline]) / concentration[baseline]) 3 100.
c For percentage increase.
d A, Asia/Australia; B, South Africa; C, South America; D, Europe/North America.
DOI: 10.1371/journal.pmed.0010019.t004
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Nevirapine, Efavirenz, and Lipid Changesrespectively). Men had a signiﬁcant increase of TGs in both
the NVP group (14.1%) and the EFV group (43.3%); women
using NVP had no signiﬁcant TG increase (6.5%), while those
using EFV had (15.9%). The effect of pVL decrease on TG
increase was quite different for patients taking NVP versus
those taking EFV. In the NVP group, the increase in TG
concentration was 17.2% for a pVL decrease less than 2.5
log10, 16.6% for a decrease between 2.5 and 3.5 log10, and
 6.1% (denoting a decrease) for a pVL decrease more than
3.5 log10. In the EFV group, these estimates were 27.4%,
37.2%, and 26.0%, respectively.
Adjusting for the variables included in the multivariable
model, the difference between patients taking NVP and those
taking EFV in HDL-c increase (9.8%; 95% CI, 3.4 16.3) and
decrease of the TC:HDL-c ratio ( 11%; 95% CI, 15.1 to 6.8)
remained statistically signiﬁcant.
Also, the difference in non-HDL-c increase ( 9.5%; 95%
CI, 14.6 to  4.4) and TG increase ( 27.2%; 95% CI, 38.0 to
 16.4) remained statistically signiﬁcant.
The difference in TC increase ( 4.4%; 95% CI, 8.0 to 0.8)
became statistically signiﬁcant. The difference between NVP
and EFV groups for the increase in LDL-c remained statisti-
cally nonsigniﬁcant ( 6.1%; 95% CI,  14.7 to 2.6).
The adjusted increase of HDL-c was 42.3% and 32.4% for
patients taking NVP and EFV, respectively (p=0.003). The
adjusted change in TC:HDL-c ratio was  4.3% for patients
taking NVP and þ6.6% for patients taking EFV (p , 0.001).
These values were 26.6% and 31.0% for TC (p=0.020),
24.4% and 33.9% for non-HDL-c (p , 0.001), 17.9% and
45.1% for TG (p , 0.001), and 35.5% and 41.5% for LDL-c (p
= 0.168). These estimates were very similar in the two
sensitivity analyses (data not shown).
The proportional changes of the different plasma lipid
concentrationsover48wkaregraphicallydepictedinFigure1.
Discussion
Initiation of an ART regimen containing NVP or EFV is
accompanied by a signiﬁcant increase of HDL-c, with
concomitant increases of TC, non-HDL-c, TGs, and LDL-c.
The proportional increase of HDL-c was signiﬁcantly larger
in the NVP treatment group compared to the EFV treatment
group, while the proportional increase of TC, non-HDL-c,
and TGs was signiﬁcantly smaller. In the NVP group, the
TC:HDL-c ratio decreased, compared to an increase in the
EFV group. These observations are different from what is
Figure 1. Change in Plasma Concentrations of Lipids and Lipoproteins
Adjusted for sex, region, pVL decrease, and CD4þ-cell increase.
DOI: 10.1371/journal.pmed.0010019.g001
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concentrations of TC, LDL-c, and TGs are reported but
without the concurrent higher levels of HDL-c [17,18].
In contrast to a small randomised study (n=67) that did
not show signiﬁcant differences between NVP and EFV [19],
the present study demonstrates a more favourable lipid
proﬁle for treatment including NVP than for treatment
including EFV in ART-naive patients.
HDL-c Increase and NNRTI
Increases of HDL-c with the use of NVP or EFV have been
described in studies for patients switching from a PI-based
regimen to a NNRTI-based regimen [20,21]. Data for ART-
naive patients starting therapy with an NNRTI-based regimen
are scarce. Van der Valk et al. reported an increase of HDL-c
of 0.44 mmol/l for patients initiating treatment with
didanosine, d4T, and NVP in the Atlantic trial [12]. Tashima
et al. reported an increase of HDL-c of 0.21 mmol/l in
patients treated with EFV and either zidovudine plus 3TC, or
indinavir [13], while Negredo et al. showed an increased HDL-
c concentration in therapy-naive patients starting a regimen
of didanosine, d4T, and EFV (0.34 mmol/l) [22].
The present study showed a clear effect of baseline HDL-c
on the proportional increase. The largest increases were seen
for patients who had an increased CHD risk based on their
low HDL-c level (,1.03 mmol/l) according to NCEP guide-
lines. But also patients with a normal HDL-c level, who are
not at an increased CHD risk, showed marked increases in
HDL-c. This baseline effect can likewise be distilled from the
other studies, where those with the lowest baseline value (0.93
mmol/l; Atlantic study [12]) showed the largest HCL-c
increase, while the smallest increase was seen in the study
with the highest baseline value (1.23 mmol/l; Tashima study
[13]). The study by Negredo et al. [21], which included
patients with similar baseline HDL-c levels as in the present
study, showed an increase of HDL-c comparable to that in the
present study (0.34 and 0.36 mmol/l, respectively). The much
more modest HDL-c-increasing effect of statins likewise
shows such a correlation with baseline level in patients
without HIV-1.
One may postulate that the HDL-c increase merely reﬂects
an adequate suppression of HIV-1 infection (‘return towards
normal’). In support, a larger decrease in pVL was associated
w i t hal a r g e ri n c r e a s eo fH D L - ci nt h ep r e s e n ts t u d y .
However, the magnitude of the HDL-c increase was only
slightly different for patients experiencing virologic failure
during these 48 wk (29.5%) and those with complete
suppression (34.0%; p=0.161), and the increases of HDL-c
remained statistically signiﬁcant even after adjustment for
pVL decrease.
Riddler et al. compared changes in lipid concentrations
before seroconversion for HIV-1, initiation of ART, and
during ART in patients using different ART regimens, which
all but one included a PI [23]. The period between
seroconversion and start of ART was characterised by
decreases in TC, LDL-c, and HDL-c.
Between initiation of ART and the ﬁrst follow-up visit
(mean, 1.3 years), the concentrations of TC and LDL-c
increased again to levels that did not differ signiﬁcantly from
before seroconversion. Such a ‘return to normal’ as a result of
ART was not seen for HDL-c. The reported increases by
Riddler et al. in TC (0.88 mmol/l) and LDL-c (0.41 mmol/l)
were of a comparable magnitude to that found for patients
taking NVP in this present study (0.97 and 0.55 mmol/l,
respectively). However, the HDL-c increase was more than
ten times smaller (0.03 mmol/l) in the Riddler et al. study than
the 0.36 mmol/l observed in patients taking NVP in the
present study, while the mean HDL-c values at which ART was
started were comparable in the two studies (1.04 and 1.0
mmol/l, respectively). This indicates that although at least
part of the change in TC and LDL-c may reﬂect a ‘return
towards normal’, the magnitude of the HDL-c increase
observed in our study must have occurred through additional
mechanisms. Since we have no information on the antiret-
roviral efﬁcacy of the regimens used in the Riddler et al.
study, we have to consider that the reported differences
between the Riddler et al. study and the present study might
be partly due to differences in HIV-1 suppression. However,
the type of PI-based regimens used in the Riddler et al. study
and the long-term adequate adherence by the patients make
large differences in antiretroviral efﬁcacy unlikely.
We are currently conducting studies to unravel whether
NVP possibly stimulates synthesis of the most important
apolipoprotein of HDL-c, apoAI, or alternatively, for
instance, decreases the clearance of HDL-c particles.
Several studies have convincingly shown that an HDL-c
increase is associated with a signiﬁcant decrease in CHD
mortality independent of changes in LDL-c [1,2]. Overall,
extrapolation of these studies indicates that a 0.025-mmol/l
increase in HDL-c is expected to be associated with a 2%–3%
reduction in CHD risk, while an increase of 1.0 mmol/l in
LDL-c will increase the CHD risk by 25%. The mean absolute
increases in HDL-c and LDL-c were 0.36 and 0.54 mmol/l,
respectively, for patients taking NVP, and 0.24 and 0.65,
respectively, for patients taking EFV. It can therefore be
estimated that, taking the observed effects on both HDL-c
and LDL-c into account, the reduction in CHD risk would be
15% for patients taking NVP and 3% for patients taking EFV
compared to ART regimens that do not include NNRTIs.
Although the differences in absolute concentrations of HDL-
c and LDL-c may seem modest when comparing the NVP and
EFV treatment groups, the combined effect of these changes
on CHD risk seems marked. It should be emphasised that
these are theoretical estimates, which do not take into
account that increases in TGs would be expected to have an
opposite effect on CHD risk. The increase in this last
parameter is, however, smaller for patients taking NVP than
for patients taking EFV. Furthermore, we do not have
information on the presence of conventional risk factors
for CHD. The actual effect of the lipid changes associated
with particular ART regimens on CHD can only be
substantiated by clinical endpoint studies.
Changes in TGs, TC, and LDL-c
The data indicate that EFV might have a more detrimental
effect on TG levels than NVP. That EFV indeed can be
associated with an increase in TGs was shown in two studies,
in which sporadical hypertriglyceridaemia was reported in
patients starting an ART regimen with EFV but without d4T
[24,25]. A difference between NVP and EFV treatment with
respect to the TG effect is also in line with a study by Negredo
et al. [20]. In this study patients were randomised to either
continue their successful PI-based regimen or to change to an
NVP-based or an EFV-based regimen. Only patients switching
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levels.
The proportional increase in TG levels with both NVP and
EFV treatment seems large, but the median absolute TG level
at week 48 was still low in both treatment groups (1.2 mmol/l
and 1.4 mmol/l, respectively). In the NCEP guidelines, a TG
concentration below 1.69 mmol/l is still considered normal
[26]. The increase in TG level is therefore probably not
clinically meaningful.
The differences between patients taking NVP and those
taking EFV in changes in TC as well as TGs are unlikely to be
explained by the concurrent use of d4T. In both treatment
groups, the percentage of patients who used d4T as part of
their regimen throughout follow-up was high (96% for the
NVP treatment group and 98% for the EFV treatment
group). This high rate of d4T use might, however, be
responsible for the impression that the increases in TC and
TGs seem to continue or even accelerate towards the end of
the study period, as opposed to a somewhat declining effect
of treatment on HDL-c after 24 wk. A possible explanation
for this may be the gradual, progressive worsening of fat
redistribution or lipodystrophy that one would expect to
occur in this continuously d4T-exposed patient population.
Both the incidence and severity of lipodystrophy are
particularly increased with d4T-containing ART regimens,
and lipodystrophy has been reported to be associated with
increased TC and TG levels [27,28,29,30,31,32]. It is therefore
conceivable that the lipid changes in the second part of the
study represent a combined effect of the NNRTI used and a
superimposed effect resulting from gradually worsening fat
redistribution.
Due to the relatively short mandatory fasting period (3 h),
the measured TG concentration might be biased, possibly
even more so given that HIV-1 infection may be associated
with reduced TG clearance following food intake [33]. As a
consequence, the estimates of calculated LDL-c might be
biased. TG levels inﬂuence changes in non-HDL-c less. The
fact that in the present study the increases of non-HDL-c,
LDL-c, and TGs are all smaller for patients taking NVP than
for patients taking EFV suggests that the LDL-c and TG
results are valid despite the potentially short mandatory
fasting periods.
ART and CHD
The relationship between ART and CHD has been the
subject of several studies, based on either clinical or validated
surrogate endpoints (like arterial intima-media thickness [34]
or endothelial wall function [35]).
Studies examining intima-media thickness in patients with
HIV-1 treated with ART, or more speciﬁcally with PI-based
ART, remain inconclusive as to whether ART use induces
accelerated intima-media thickening [36,37,38,39]. PI use may
have a detrimental effect on endothelial function in vivo, or
accelerate foam cell formation in vitro [40,41].
In a retrospective clinical endpoint study including almost
37,000 patients, Bozzette et al. reported no relation between
ART use and hospital admission for cardiovascular events
[42], a ﬁnding conﬁrmed in the ‘Kaiser Permanente’ cohort
[43]. However, the large prospective ‘data collection on
adverse events of anti-HIV drugs’ (D:A:D) study, speciﬁcally
designed to identify the extent to which ART may be
associated with increased CHD risk, did show that every
additional year of ART use was associated with a 26%
increased risk of myocardial infarction [10]. The latter
resembles the results from other retrospective and prospec-
tive studies [44,45,46]. The relatively high prevalence of
known CHD risk factors in patients with HIV-1, especially
smoking [47,48], complicates interpretation of the relation
between ART use and CHD. None of these studies allows
deﬁnitive conclusions to be made about the potentially
different degree of risk associated with particular ART
regimens.
Limitations and Possible Biases
The selection of patients remaining on their allocated
treatment for the full 48 wk might have introduced sampling
bias with inﬂated treatment effects. The reported estimates
from this OT analysis were very similar to the estimates from
the intention-to-treat analysis. This is caused by the fact that
only a few patients who were not included in the OT analyses
changed their drug regimen by adding a PI that could
potentially inﬂuence the lipid estimates. The majority
remained on their randomised treatment but were insufﬁ-
ciently adherent (or lost to follow-up on their original
regimen) to meet the criteria for being eligible for the OT
analysis. Patients replacing their assigned NNRTI by the
NNRTI from the other treatment group of the study would
have little effect on the lipid estimates, since both NNRTIs
show changes in lipid concentrations, which go in the same
direction. Another possible reason for the similarity between
these two analyses could be the relatively late timing of
treatment changes (mean of 75 d for patients taking NVP and
95 d for patients taking EFV). The fact that the second
sensitivity analysis also showed comparable results indicates
that modelling of data did not affect the lipid estimates.
A limitation of the present study is the lack of data on
conventional CHD risk factors like smoking. The 2NN being a
randomised study, it may be expected that these and other
confounding variables are equally distributed over the treat-
ment groups. Possible residual confounding, however, cannot
be excluded, and the results should therefore be interpreted
cautiously.
Conclusion
While awaiting the results of future studies, the less
atherogenic lipid proﬁle of patients taking NVP in compar-
ison to those of patients taking EFV may be among the
various factors to consider when selecting the most appro-
priate initial ART regimen, particularly for those patients
with HIV-1 with a signiﬁcant a priori CHD risk. Including
such a consideration seems warranted, since treatment of the
ART-induced lipid changes with currently licensed lipid-
lowering agents is not without problems. Most of the available
statins except pravastatin and ﬂuvastatin, are metabolised
through cytochrome isoenzyme CYP3A4, just as the PIs and
NNRTIs are, providing concern for potential drug–drug
interactions. Furthermore, statin therapy in patients using a
PI-based regimen is in general not able to reduce the lipid
concentrations to normal levels [49,50]. Studies on the
effectiveness of gemﬁbrozil in patients on a PI-based regimen
show conﬂicting results [51,52,53]. Finally, the introduction of
yet another type of medication in a patient population that
often needs to use not only ART but also a considerable
amount of concomitant medication might jeopardise treat-
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sustained success of ART treatment.
Use of the novel PI atazanavir may also be considered an
attractive option in patients at high risk of CHD, given that it
is associated with markedly smaller increases of TC, LDL-c,
and TGs compared to previously available PI-based regimens
[54,55], but it lacks the concurrently large increase in HDL-c
seen with NNRTI-based regimens.
The reported increase of HDL-c concentration with
NNRTI use is far greater than that seen with conventional
lipid-lowering drugs and is of a similar magnitude as the
HDL-c increases reported with the most powerful HDL-c-
increasing drugs that are currently in clinical development
[6,56]. Asztalos et al. reported the effect on HDL-c for ﬁve
major statins in patients with CHD [57]. They concluded that
the HDL-c increase was between 4% (simvastatin) and 11%
(pravastatin and lovastatin). Treatment with ﬂuvastatin or
lovastatin proved to be most effective in patients with a low
baseline HDL-c level [56,58]. Clinical trials assessing the
effects of ﬁbrates reported an HDL-c increase of 6% and 11%
for gemﬁbrozil [2,59], and 18% for bezaﬁbrate [60].
Unravelling the mechanism or mechanisms by which NVP
and EFV raise HDL-c could contribute to the development of
novel interventions aimed at increasing HDL-c and thereby
ultimately to reducing CHD risk in the population at large.
Acknowledgments
The study was investigator initiated and ﬁnancially supported by
Boehringer Ingelheim. This company had a nonbinding input on
issues of study design and analyses, which did not lead to any
signiﬁcant inﬂuence on the resulting design and analyses. The
company was allowed to provide comments on the manuscript in
progress, but had no inﬂuence on reporting of the data or the
decision to publish. All investigators, as well as Boehringer Ingelheim,
had full access to the data after ofﬁcial closure of the database.
Investigators
Argentina: H. Laplume ´, M. B. Lasala, M. H. Losso, E. Bogdanowicz,
R. Lattes, A. Krolewiecki, C. Zala, C. Orcese, S. Terlizzi, A. Duran, J.
Ebensrteijn.
Australia: M. Bloch, O. Russell, D. B. Russell, N. R. Roth, B. Eu, D.
Austin, A. Gowers, D. Quan.
Belgium: J. Demonty, R. Peleman, B. Vandercam, D. Vogelaers, B.
van der Gucht, F. van Wanzeele, M. M. Moutschen.
Brazil: R. Badaro, B. Grinsztejn, M. Schechter, D. Uip, E. N. Netto,
S. S.Coelho, F. Badaro ´, J. H. Pilotto, A. Schubach, M. L. Barros, O. H.
M. Leite, C. R. V. Kiffer, C. T. Wunsch, D. Nunes, A. Catalani, R. de
Cassia Alves Lira, T. J. Dossin, M. T. D’Allo ´ de Oliveira, S. Martini.
Canada: B. Conway, J. J. de Wet, J. S. G. Montaner, C. Murphy, B.
Woodfall, P. Sestak, P. Phillips, V. Montessori, M. Harris, A.
Tesiorowski, B. Willoughby, R. Voigt, J. Farley, R. Reynolds, S.
Devlaming.
France: J. M. Livrozet, W. Rozenbaum, D. Sereni, M. A.Valantin, C.
Lascoux, B. Milpied, C. Brunet, E. Billaud, A. Huart, V. Reliquet, M. F.
Charonnat, M. Sicot, J. L. Esnault, L. Slama.
Germany: S. Staszewski, M. Bickel.
Greece: M. K. Lazanas, N. Stavrianeas, N. Mangafas, I. Zagoreos, S.
Kourkounti, V. Paparizos, C. Botsi.
Ireland: S. Clarke, E. Brannigan, N. Boyle.
Italy: A. Chiriani, F. Leoncini, F. Montella, L. Francesco, S. Ambu,
A. Farese, M. Gargiulo, F. Di Sora, F. Lavria, F. Folgori.
P o l a n d :M .B e n i o w s k i ,A .B o r o n - K a c z m a r s k a ,W .H a l o t a ,D .
Prokopowicz, D. B. Bander, M. L. P. Leszuzyszyn-Pynka, A. W. Wnuk,
E. Bakowska, P. Pulik, R. Flisiak, A. Wiercinska-Drapalo, E. Mularska,
A. Witor.
Portugal: F. Antunes, R. S. E. Sarmento, M. Doroana, A. A. Horta,
O. Vasconcelos.
South Africa: S. M. Andrews, C. B. Huisamen, D. Johnson, O.
Martin, L.-G. Bekker, G. Maartens, D. Wilson, C. J. Visagie, N. J. David,
M. Rattley, E. Nettleship, D. J. Martin, V. Keyser, T. M. Moraites, M. A.
Moorhouse, J. A. Pitt, C. J. Orrell, C. Bester, R. Parboosing, P.
Moodley, V. Gathiram, D. Woolf.
Switzerland: E. Bernasconi, L. Magenta.
Thailand: P. Cardiello, E. Kroon, C. Ungsedhapand.
United Kingdom: M. Fisher, E. G. L. Wilkins, E. Stockwell, J. Day, R.
S. Daintith, N. Perry, C. Timaeus, J. McIntosh-Roffet, A. Powell, M.
Youle, M. Tyrer, S. Madge, A. Drinkwater, Z. Cuthbertson, A. Carroll.
United States: S. Becker, H. Katner, D. Rimland, M. S. Saag, M.
Thompson, M. Witt, M. M. Aguilar, A. LaVoy, M. Illeman, M.
Guerrero.
Data Safety and Monitoring Board: J. Gatell (chair), E. Belsey, B.
Hirschel.
Project management: L. Dam, A. Potarca, M. Cronenberg, L.
Kreekel.
Data management: R. Meester, J. Khodabaks, H.-J. Botma, N. Esrhir,
I. Farida, M. Feenstra, K. Jansen, A. Klotz, M. Mulder, G. Ruiter.
Laboratory: C. B. Bass, E. Pluymers, E. de Vlegelaer (Labcorp), R.
Leeneman (Virtual Central Laboratory).
Boehringer Ingelheim: H. Carlier, E. van Steenberge, P. Robinson.
Competing Interests
FvL has received travel grants and honoraria for presentations from
Boehringer Ingelheim and travel grants from GlaxoSmithKline. PP
has received research grants and honoraria for speaking from
GlaxoSmithKline, Bristol-Myers Squibb, Roche, Merck Sharp and
Dohme, and Boerhinger Ingleheim. BG has received grants and
honoraria from Abbott Pharmaceuticals, GlaxoSmithKline, Bristol-
Myers Squibb, Gilead, and Boehringer Ingleheim. FR has received
research grants and honoraria from GlaxoSmithKline, Roche, Bristol-
Myers Squibb, Abbott, and Boehringer Ingleheim. RW is conducting
clinical research supported by GlaxoSmithKline, Boehringer Ingel-
heim, Pﬁzer, and Bristol-Myers Squibb. MB is currently conducting
clinical studies supported by Boehringer Ingelheim, Bristol-Myers
Squibb, and Merck. CK has received grants and honoraria for
speaking from Bristol-Myers Squibb, GlaxoSmithKline, Boehringer
Ingelheim, Bayer, and Roche. MS has received research grants, travel
grants, and honoraria for speaking from Abbott, Bristol-Myers
Squibb, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Merck,
and Roche. RLM has received honoraria for consultancies from
Boehringer Ingelheim and Bristol-Myers Squibb. AH has received
honoraria for presentations from Boehringer Ingleheim. DBH is
employed by Boehringer Ingelheim, the manufacturer of one of the
trial medications. JMAL has received honoraria as an advisor for
GlaxoSmithKline, Boehringer Ingelheim, Bristol-Myers Squibb,
Roche, Merck Sharp and Dohme, Schering-Plough, Bayer, Shire
Pharmaceuticals, Agouron/Pﬁzer, and Virco/Tibotec. PR, in the last
ﬁve years, has received honoraria for speaking engagements from
Boehringer Ingelheim.
JMAL is a member of the editorial board of PLoS Medicine. &
References
1. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, et al. (1988) Lipid
alterations and decline in the incidence of coronary heart disease in the
Helsinki Heart Study. JAMA 260: 641–651.
2. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al. (1999)
Gemﬁbrozil for the secondary prevention of coronary heart disease in men
with low levels of high-density lipoprotein cholesterol. Veterans Affairs
High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N
Engl J Med 341: 410–418.
3. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, et al. (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in
patients with acute coronary syndromes: A randomized controlled trial.
JAMA 290: 2292–2300.
4. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, et al. (2003)
Restoration of endothelial function by increasing high-density lipoprotein
in subjects with isolated low high-density lipoprotein. Circulation 107:
2944–2948.
5. Brewer HB Jr(2004) High-density lipoproteins: A new potential therapeutic
target for the prevention of cardiovascular disease. Arterioscler Thromb
Vasc Biol 24: 387–391.
6. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, et al.
(2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL
cholesterol. N Engl J Med 350: 1505–1515.
7. Carr A, Miller J, Law M, Cooper DA (2000) A syndrome of lipoatrophy,
lactic acidaemia and liver dysfunction associated with HIV nucleoside
analogue therapy: Contribution to protease inhibitor-related lipodys-
trophy syndrome. AIDS 14: F25–F32.
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e19 072
Nevirapine, Efavirenz, and Lipid Changes8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, et al.
(1999) Diagnosis, prediction, and natural course of HIV-1 protease-
inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus:
A cohort study. Lancet 353: 2093–2099.
9. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, et al. (1999) Impaired
glucose tolerance, beta cell function and lipid metabolism in HIV patients
under treatment with protease inhibitors. AIDS 13: F63–F70.
10. Friis-Moller N, Sabin CA, Weber R, d’Arminio Monforte A, El-Sadr WM, et
al. (2003) Combination antiretroviral therapy and the risk of myocardial
infarction. N Engl J Med 349: 1993–2003.
11. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, et al. (1999)
Atherogenic dyslipidemia in HIV-infected individuals treated with pro-
tease inhibitors. The Swiss HIV Cohort Study. Circulation 100: 700–705.
12. van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, et al.
(2001) Nevirapine-containing antiretroviral therapy in HIV-1 infected
patients results in an anti-atherogenic lipid proﬁle. AIDS 15: 2407–2414.
13. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP (2003) Lipid
changes in patients initiating efavirenz- and indinavir-based antiretroviral
regimens. HIV Clin Trials 4: 29–36.
14. Gotto AM Jr(2001) Low high-density lipoprotein cholesterol as a risk factor
in coronary heart disease: A working group report. Circulation 103: 2213–
2218.
15. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, et al. (2004)
Comparison of ﬁrst-line antiretroviral therapy with regimens including
nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: A
randomised open-label trial, the 2NN Study. Lancet 363: 1253–1263.
16. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the
concentration of low-density lipoprotein cholesterol in plasma, without
use of the preparative ultracentrifuge. Clin Chem 18: 499–502.
17. Stein JH, Wu Y, Kawabata H, Iloeje UH (2003) Increased use of lipid-
lowering therapy in patients receiving human immunodeﬁciency virus
protease inhibitors. Am J Cardiol 92: 270–274.
18. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, et al. (2004)
Lipid proﬁles in HIV-infected patients receiving combination antiretro-
viral therapy: Are different antiretroviral drugs associated with different
lipid proﬁles? J Infect Dis 189: 1056–1074.
19. Nunez M, Soriano V, Martin-Carbonero L, Barrios A, Barreiro P, et al.
(2002) SENC (Spanish efavirenz vs. nevirapine comparison) trial: A
randomized, open-label study in HIV-infected naive individuals. HIV Clin
Trials 3: 186–194.
20. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, et al. (2002) Virological,
immunological, and clinical impact of switching from protease inhibitors
to nevirapine or to efavirenz in patients with human immunodeﬁciency
virus infection and long-lasting viral suppression. Clin Infect Dis 34.
21. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion
of metabolic abnormalities after switching from HIV-1 protease inhibitors
to nevirapine. AIDS 13: 805–810.
22. Negredo E, Ribalta J, Ferre R, Salazar J, Rey-Joly C, et al. (2004) Efavirenz
induces a striking and generalized increase of HDL-cholesterol in HIV-
infected patients. AIDS 18: 819–821.
23. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, et al. (2003) Impact of HIV
infection and HAART on serum lipids in men. JAMA 289: 2978–2982.
24. Molina JM, Ferchal F, Rancinan C, Rafﬁ F, Rozenbaum W, et al. (2000)
Once-daily combination therapy with emtricitabine, didanosine, and
efavirenz in human immunodeﬁciency virus-infected patients. J Infect
Dis 182: 599–602.
25. Fisac C, Fumero E, Crespo M, Roson B, Virgili N, et al. (2004) Metabolic
changes in patients switching from a protease inhibitor-containing
regimen to abacavir (ABC), efavirenz (EFV), or nevirapine (NVP): 24-
Month results of a randomized study. Abstract 78. Program and Abstracts
of the 11th Conference on Retroviruses and Opportunistic Infections (11
th
CROI); 2004 February 8–11; San Francisco, California. Alexandria (Virgin-
ia): Foundation for Retrovirology and Human Health. p. 105.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults(2001) Executive summary of the third report of the
National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
(adult treatment panel III). JAMA 285: 2486–2497.
27. Nolan D, Mallal S (2004) The role of nucleoside reverse transcriptase
inhibitors in the fat redistribution syndrome. J HIV Ther 9: 34–40.
28. Nolan D, Hammond E, James I, McKinnon E, Mallal S (2003) Contribution
of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoa-
trophy from the population to the cellular level. Antivir Ther 8: 617–626.
29. Dube MP, Zackin R, Tebas P, Roubenoff R, Mulligan K, et al. (2002)
Prospective study of regional body composition in antiretroviral-naive
subjects randomized to receive zidovudine plus lamivudine or didanosine
plus stavudine combined with nelﬁnavir, efavirenz, or both: A5005s, a
substudy of ACTG 384. Program and Abstracts of the 4th International
Workshop on Adverse Drug Reactions and Lipodystropy in HIV; 2002
September 22–25; San Diego, California. London: International Medical
Press. p. L18.
30. Heath KV, Hogg RS, Chan KJ, Harris M, Montessori V, et al. (2001)
Lipodystrophy-associated morphological, cholesterol and triglyceride
abnormalities in a population-based HIV/AIDS treatment database. AIDS
15: 231–239.
31. Sattler F (2003) Body habitus changes related to lipodystrophy. Clin Infect
Dis 36: S84–S90.
32. McComsey GA, Ward DJ, Hessenthaler SM, Sension MG, Shalit P, et al.
(2004) Improvement in lipoatrophy associated with highly active anti-
retroviral therapy in human immunodeﬁciency virus-infected patients
switched from stavudine to abacavir or zidovudine: The results of the
TARHEEL study. Clin Infect Dis 38: 263–270.
33. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, et al. (1992)
Lipids, lipoproteins, triglyceride clearance, and cytokines in human
immunodeﬁciency virus infection and the acquired immunodeﬁciency
syndrome. J Clin Endocrinol Metab 74: 1045–1052.
34. Simon A, Gariepy J, Chironi G, Megnien JL, Levenson J (2002) Intima-
media thickness: A new tool for diagnosis and treatment of cardiovascular
risk. J Hypertens 20: 159–169.
35. Vita JA, Keaney JF Jr (2002) Endothelial function: A barometer for
cardiovascular risk? Circulation 106: 640–642.
36. Seminari E, Pan A, Voltini G, Carnevale G, Maserati R, et al. (2002)
Assessment of atherosclerosis using carotid ultrasonography in a cohort of
HIV-positive patients treated with protease inhibitors. Atherosclerosis 162:
433–438.
37. Chironi G, Escaut L, Gariepy J, Cogny A, Monsuez JJ, et al. (2003) Brief
report: Carotid intima-media thickness in heavily pretreated HIV-infected
patients. J Acquir Immune Deﬁc Syndr 32: 490–493.
38. Mercie P, Thiebaut R, Lavignolle V, Pellegrin JL, Yvorra-Vives MC, et al.
(2002) Evaluation of cardiovascular risk factors in HIV-1 infected patients
using carotid intima-media thickness measurement. Ann Med 34: 55–63.
39. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, et al. (2001)
Premature atherosclerosis in HIV-infected individuals—Focus on protease
inhibitor therapy. AIDS 15: 329–334.
40. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, et al. (2003) HIV
protease inhibitors promote atherosclerotic lesion formation independent
of dyslipidemia by increasing CD36-dependent cholesteryl ester accumu-
lation in macrophages. J Clin Invest 111: 389–397.
41. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, et al. (2001)
Use of human immunodeﬁciency virus-1 protease inhibitors is associated
with atherogenic lipoprotein changes and endothelial dysfunction.
Circulation 104: 257–262.
42. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular
and cerebrovascular events in patients treated for human immunodeﬁ-
ciency virus infection. N Engl J Med 348: 702–710.
43. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S (2002) Do protease
inhibitors increase the risk for coronary heart disease in patients with HIV-
1 infection? J Acquir Immune Deﬁc Syndr 30: 471–477.
44. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, et al. (2003) Coronary
heart disease in HIV-infected individuals. J Acquir Immune Deﬁc Syndr 33:
506–512.
45. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, et al.
(2002) Protease inhibitors and cardiovascular outcomes in patients with
HIV-1. Lancet 360: 1747–1748.
46. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D (2003)
Increased risk of myocardial infarction with duration of protease inhibitor
therapy in HIV-infected men. AIDS 17: 2479–2486.
47. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, et al. (2003)
Cardiovascular disease risk factors in HIV patients—Association with
antiretroviral therapy. Results from the DAD study. AIDS 17: 1179–1193.
48. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, et al. (2003) Risk
factors for coronary heart disease in patients treated for human
immunodeﬁciency virus infection compared with the general population.
Clin Infect Dis 37: 292–298.
49. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J (1998)
Atorvastatin and gemﬁbrozil for protease-inhibitor-related lipid abnor-
malities. Lancet 352: 1031–1032.
50. Chuck SK, Penzak SR (2002) Risk-beneﬁt of HMG-CoA reductase inhibitors
in the treatment of HIV protease inhibitor-related hyperlipidaemia. Expert
Opin Drug Saf 1: 5–17.
51. Miller J, Brown D, Amin J, Kent-Hughes J, Law M, et al. (2002) A
randomized, double-blind study of gemﬁbrozil for the treatment of
protease inhibitor-associated hypertriglyceridaemia. AIDS 16: 2195–2200.
52. Calza L, Manfredi R, Chiodo F (2003) Statins and ﬁbrates for the treatment
of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17:
851–859.
53. Bonnet F, Balestre E, Thiebaut R, Mercie P, Dupon M, et al. (2004) Fibrates
or statins and lipid plasma levels in 245 patients treated with highly active
antiretroviral therapy. Aquitaine Cohort, France, 1999–2001. HIV Med 5:
133–139.
54. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S (2003) Results of a
phase 2 clinical trial at 48 weeks (AI424–007): A dose-ranging, safety, and
efﬁcacy comparative trial of atazanavir at three doses in combination with
didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune
Deﬁc Syndr 32: 18–29.
55. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, et al. (2003) Dose-
ranging, randomized, clinical trial of atazanavir with lamivudine and
stavudine in antiretroviral-naive subjects: 48-Week results. AIDS 17: 2603–
2614.
56. Downs JR, Clearﬁeld M, Weis S, Whitney E, Shapiro DR, et al. (1998)
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e19 073
Nevirapine, Efavirenz, and Lipid ChangesPrimary prevention of acute coronary events with lovastatin in men and
women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air
Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–
1622.
57. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, et al.
(2002) Comparing the effects of ﬁve different statins on the HDL
subpopulation proﬁles of coronary heart disease patients. Atherosclerosis
164: 361–369.
58. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, et al. (1999)
Inﬂuence of low HDL on progression of coronary artery disease and
response to ﬂuvastatin therapy. Circulation 99: 736–743.
59. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. (1987)
Helsinki Heart Study: Primary-prevention trial with gemﬁbrozil in middle-
aged men with dyslipidemia. Safety of treatment, changes in risk factors,
and incidence of coronary heart disease. N Engl J Med 317: 1237–1245.
60. Anonymous(2000) Secondary prevention by raising HDL cholesterol and
reducing triglycerides in patients with coronary artery disease: The
Bezaﬁbrate Infarction Prevention (BIP) Study. Circulation 102: 21–27.
Patient Summary
Why Did the Researchers Do the Study? Drugs used to treat HIV
(antiretroviral drugs) help patients to live longer, but they can also have
some serious side effects. For example, the longer people take them, the
higher the risk they’ll get heart disease. Why? Part of the reason is that
many—though not all—antiretroviral drugs cause changes in cholesterol
levels in the bloodstream (an increase in the amount of ‘‘bad’’
cholesterol and a reduction in the amount of ‘‘good’’ cholesterol).
Two of the most commonly prescribed antiretroviral drugs are
nevirapine and efavirenz. Previous smaller studies showed that treat-
ment with either of the drugs could increase the amount of ‘‘good’’
cholesterol. The researchers now wanted to directly compare these
drugs to find out what effect they had on patients’ cholesterol levels in a
much larger group of patients.
What Did the Researchers Do? The scientists studied adults with HIV
who had never previously taken antiretroviral drugs. All of the patients
then took ‘‘triple therapy’’—a combination of three antiretroviral drugs.
Some of the patients took nevirapine as part of their triple therapy,
whereas some took efavirenz. The researchers took blood samples
regularly for almost a year and measured patients’ cholesterol levels.
What Did the Researchers Find? They confirmed that both nevirapine
and efavirenz indeed have a beneficial effect on patients’ cholesterol
levels. They both increase the amount of ‘‘good’’ cholesterol in the
bloodstream. The increase was higher with nevirapine than with
efavirenz.
What Does This Study Mean for Patients? If your treatment includes
nevirapine or efavirenz (particularly nevirapine), this can raise your level
of ‘‘good’’ cholesterol.
The results of the study may be especially important if you are already at
risk for heart disease. In other words, if you have risk factors for heart
disease—high blood pressure, diabetes, heart disease running in your
family, being a smoker—it may be beneficial for your HIV medications to
include nevirapine. If you smoke, you can lower your risk of heart disease
by quitting. If you have high blood pressure or diabetes, treating these
conditions can also lower your risk of heart disease.
What Are the Problems with the Study? Although the researchers
showed that nevirapine and efavirenz can have a beneficial effect on
cholesterol levels, they haven’t actually shown that this reduces patients’
risk of getting heart disease.
The study was funded by the company that produces nevirapine. In
theory this could have affected the results (research has shown that
company-sponsored studies are more likely to produce results favorable
to the company than studies without sponsorship). The study, however,
was carried out by a network of independent investigators who state
that the company had no influence on the reporting of the results.
Where Can I Get More Information? You can get more information on
HIV and its treatment from the Terrence Higgins Trust (www.tht.org.uk),
AIDS.ORG (www.aids.org), and The Body (www.thebody.com).
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